ChemDiv, a global provider of integrated drug discovery solutions, announced on Thursday that it has extended its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a potential oral antiviral treatment for COVID-19.

This follows the recent progress by US-based Traws Pharma Inc (NASDAQ:TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by the end of 2025.

Ratutrelvir is a ritonavir-free Main protease (Mpro/3CL) inhibitor that was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams.

ChemDiv says that it used Molsoft's rational drug design platform and Expert Systems' predictive pharmacology tools to develop ratutrelvir to differentiate from existing COVID-19 treatments by providing high potency against a wide range of native and resistant SARS-CoV-2 strains, a simplified 10-day treatment regimen, and elimination of ritonavir co-administration -- potentially avoiding drug-drug interactions that limit patient eligibility for present therapies.

Ratutrelvir is currently being assessed in two Phase 2 studies: a non-inferiority trial comparing ratutrelvir to PAXLOVID in newly diagnosed COVID-19 patients, and a single-arm trial in PAXLOVID-ineligible patients -- a vulnerable population with limited treatment options.